|
|
|
Insider
Information: |
Tobias Jeffrey K |
Relationship: |
EVP, R&D & CMO |
City: |
San Carlos |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
43,483 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$4,205,147 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
43,483 |
|
|
Total
Value |
$4,205,147 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Neurogesx Inc |
NGSX |
EVP Research & Dev & CMO |
2011-05-18 |
4,999 |
2009-11-25 |
0 |
Premium* |
|
Jazz Pharmaceuticals Inc |
JAZZ |
EVP, R&D & CMO |
2015-03-05 |
38,484 |
2012-08-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
48 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-25 |
4 |
OE |
$1.25 |
$11,629 |
D/D |
9,303 |
15,968 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-25 |
4 |
S |
$8.38 |
$77,976 |
D/D |
(9,303) |
6,665 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-27 |
4 |
OE |
$1.25 |
$775 |
D/D |
620 |
7,285 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-27 |
4 |
S |
$8.27 |
$5,130 |
D/D |
(620) |
6,665 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-30 |
4 |
OE |
$1.25 |
$15,096 |
D/D |
12,077 |
18,742 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Chief Medical Officer |
|
2009-11-30 |
4 |
S |
$8.07 |
$97,494 |
D/D |
(12,077) |
6,665 |
0 |
- |
|
NGSX |
Neurogesx Inc |
EVP Research & Dev & CMO |
|
2011-05-12 |
4 |
S |
$2.91 |
$1,746 |
D/D |
(600) |
8,180 |
0 |
- |
|
NGSX |
Neurogesx Inc |
EVP Research & Dev & CMO |
|
2011-05-13 |
4 |
S |
$2.81 |
$2,060 |
D/D |
(733) |
7,447 |
0 |
- |
|
NGSX |
Neurogesx Inc |
EVP Research & Dev & CMO |
|
2011-05-16 |
4 |
S |
$2.84 |
$3,786 |
D/D |
(1,333) |
7,447 |
0 |
- |
|
NGSX |
Neurogesx Inc |
EVP Research & Dev & CMO |
|
2011-05-17 |
4 |
S |
$2.73 |
$3,639 |
D/D |
(1,333) |
6,114 |
0 |
- |
|
NGSX |
Neurogesx Inc |
EVP Research & Dev & CMO |
|
2011-05-18 |
4 |
S |
$2.82 |
$3,144 |
D/D |
(1,115) |
4,999 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D & CMO |
|
2015-02-10 |
4 |
OE |
$46.83 |
$234,150 |
D/D |
5,000 |
40,063 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D & CMO |
|
2015-02-10 |
4 |
AS |
$166.48 |
$834,118 |
D/D |
(5,000) |
35,063 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D & CMO |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,755 |
40,818 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D & CMO |
|
2015-02-27 |
4 |
D |
$170.09 |
$119,743 |
D/D |
(704) |
40,114 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D & CMO |
|
2015-03-05 |
4 |
D |
$174.76 |
$284,859 |
D/D |
(1,630) |
38,484 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2012-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
47,500 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-08-09 |
4 |
D |
$80.88 |
$265,933 |
D/D |
(3,288) |
44,405 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-08-12 |
4 |
AS |
$80.77 |
$605,775 |
D/D |
(7,500) |
44,405 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-08-12 |
4 |
OE |
$46.83 |
$351,225 |
D/D |
7,500 |
51,905 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-09-09 |
4 |
AS |
$87.11 |
$435,550 |
D/D |
(5,000) |
44,405 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-09-09 |
4 |
OE |
$46.83 |
$234,150 |
D/D |
5,000 |
49,405 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-10-14 |
4 |
AS |
$82.53 |
$413,118 |
D/D |
(5,000) |
44,405 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
EVP, Research & Dev and CMO |
|
2013-10-14 |
4 |
OE |
$46.83 |
$234,150 |
D/D |
5,000 |
49,405 |
0 |
- |
|
48 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|